Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs

Peter Sandercock, Eivind Berge, Martin Dennis, John Forbes, Peter Hand, Joseph Kwan, Steff Lewis, Richard Lindley, Aileen Neilson, Joanna Wardlaw

Research output: Contribution to journalArticlepeer-review

Abstract

Thrombolytic therapy is licensed for use in highly selected patients with acute ischemic stroke. We aimed to model the health economic impact of limited use of thrombolytic therapy and to assess whether it was likely to be cost-effective when used more widely in the UK National Health Service (NHS).
Original languageEnglish
Pages (from-to)1490-7
Number of pages8
JournalStroke
Volume35
Issue number6
DOIs
Publication statusPublished - 22 Mar 2004

Keywords

  • Acute Disease
  • Brain Ischemia
  • Cost-Benefit Analysis
  • Great Britain
  • Humans
  • Models, Economic
  • Recombinant Proteins
  • Stroke
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator

Fingerprint

Dive into the research topics of 'Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs'. Together they form a unique fingerprint.

Cite this